FDA Staff Find No Major Deficiencies in Moderna's mRNA Flu Vaccine as Panel Vote Looms

Briefing documents released June 16 signal a sharp turnaround from February's refusal-to-file letter — but approval remains weeks away, and FDA has flagged real evidence gaps.

Federal regulators said Monday that Moderna’s experimental mRNA seasonal influenza vaccine has no major deficiencies in its license application, a significant reversal of fortune for a product the agency had refused to review just four months earlier.

The FDA released briefing documents on June 16, 2026, ahead of a scheduled Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting set for June 18, in which an independent expert panel will assess whether the benefits of MFLUSIVA (mRNA-1010) outweigh its risks for adults 50 years of age and older. The committee’s vote is advisory and nonbinding; it does not constitute approval.

The vaccine, developed by Moderna TX Inc. under Biologics License Application STN 125869/0, would be the first mRNA-based seasonal influenza vaccine to receive FDA approval in the United States if the agency ultimately clears it. The agency’s PDUFA action date — the deadline by which FDA has committed to completing its review — is August 5, 2026.

A turbulent path to the panel

In early February 2026, FDA’s Center for Biologics Evaluation and Research Director Vinay Prasad signed a refusal-to-file letter, declining to review Moderna’s initial submission on the grounds that the comparator used in the company’s Phase 3 trial did not reflect the best-available standard of care in the United States at the time of the study.

Days later, the agency reversed course after Moderna proposed a revised regulatory pathway: full traditional approval for adults aged 50 to 64 years, where efficacy data against a standard-dose comparator were considered sufficient, and accelerated approval for adults 65 and older based on immunogenicity data against a high-dose comparator. Under accelerated approval, Moderna would be required to conduct a post-marketing confirmatory study to secure full approval for the older cohort.

What the briefing documents say

The June 16 briefing documents reflect FDA staff’s findings under that revised framework. Agency scientists concluded that MFLUSIVA met prespecified sequential efficacy and immunogenicity criteria and identified no major safety signals or imbalances in adverse events or deaths between treatment and comparator groups.

FDA staff nonetheless identified several evidence gaps that VRBPAC panelists are expected to probe. Efficacy data derive from a single influenza season, leaving open questions about performance across seasons with differing circulating strains. The briefing also flagged an absence of co-administration data — no trials have evaluated MFLUSIVA given alongside COVID-19, respiratory syncytial virus, or pneumococcal vaccines, all commonly administered to older adults during the same clinical visits. Immunocompromised individuals and frail older adults were not well-represented in the pivotal studies.

Tomorrow, VRBPAC panelists are expected to vote separately on the benefit-risk profile of MFLUSIVA in each age group: adults 50 through 64, and adults 65 and older. A favorable committee vote would be a positive signal, but FDA is not bound by the panel’s recommendation and has until August 5 to render a final decision.

A positive briefing document is not approval. An advisory committee vote in favor is not approval. Only the agency’s written action by the PDUFA date constitutes a regulatory determination.

Trace · every claim, sourced

Reported and written by Marcus Webb, FDA & Regulatory Desk, then each load-bearing claim was bound to the primary source it rests on and checked out-of-band against that source before publication. The full mapping is below — nothing here is taken on faith.

FDA briefing documents released June 16, 2026 found no major deficiencies in Moderna's BLA for MFLUSIVA (mRNA-1010).

source on file

VRBPAC is scheduled to meet June 18, 2026 to consider MFLUSIVA for adults 50 years and older; BLA STN 125869/0.

source on file

FDA issued a refusal-to-file letter in February 2026, citing the trial comparator did not reflect best-available standard of care.

source on file

FDA reversed course and accepted a revised pathway: full traditional approval for adults 50-64; accelerated approval for adults 65+ based on immunogenicity data.

source on file

FDA PDUFA action date for MFLUSIVA is August 5, 2026.

source on file

FDA briefing flagged evidence gaps: single-season efficacy data, absence of co-administration data (COVID-19, RSV, pneumococcal vaccines), limited data in immunocompromised and frail older adults.

source on file

VRBPAC will vote separately on benefit-risk for adults 50-64 and adults 65 and older.

source on file

After publication, a separate AI panel re-verifies every edition against these same sources. The running claim-confirmation rate and every correction are public on the accuracy ledger.